News

Both a community pharmacist and a member of the public complained to the MHRA on March 20, 2006 about the free offer of medicines as an ‘on-the-shelf’ sales

A fungus, called Fusarium, is thought to cause the infection that has so far been found in 109 people and is being investigated by public health authorities in

The phase I clinical trial is designed as a double blind, single dose-escalation study and will be conducted at Sourasky Medical Center in Tel Aviv. BL-1020 is an

In a series of reports on ‘disease-mongering’, the Public Library of Science Medicine suggests that pharmaceutical companies intentionally widen the boundaries of illness in order to expand the

Approximately 130,000 multiple sclerosis (MS) patients are receiving either FDA-approved interferon beta-1a weekly (Biogen Idec’s Avonex) or glatiramer acetate daily (Teva’s Copaxone) to treat relapsing forms of MS.

Anna Bligh, Queensland deputy premier, treasurer and minister for state development, trade and innovation, has announced a $865,000 grant for the University of Queensland’s (UQ) Centre for Integrated

Based on available efficacy data, the independent data monitoring board said that enrollment should be terminated under the current protocol as it saw “very little chance for significant

The unique properties of the hollow shell nano-particles, known as polymersomes, allow them to deliver two distinct drugs, paclitaxel (marketed as Taxol by Bristol-Myers Squibb), and doxorubicin directly

The trial met the primary efficacy endpoint of improved exercise capacity for both ambrisentan dose groups, with a good safety profile and no observed liver function abnormalities in